Adenoviral Expression of a Truncated S1 Subunit of SARS-CoV Spike Protein Results in Specific Humoral Immune Responses Against SARS-CoV in Rats

Overview

Journal Virus Res

Specialty Microbiology

Date 2005 Jul 19

PMID 16022898

Citations 32

Authors

Ran-Yi Liu

Li-Zhi Wu

Bi-Jun Huang

Jia-Ling Huang

Yan-Ling Zhang

Miao-La Ke

Jun-Mei Wang

Wei-Ping Tan

Ru-Hua Zhang

Han-Kui Chen

Yi-Xin Zeng

Wenlin Huang

Affiliations

Soon will be listed here.

Abstract

The causative agent of severe acute respiratory syndrome (SARS) has been identified as SARS-associated coronavirus (SARS-CoV), but the prophylactic treatment of SARS-CoV is still under investigation. We constructed a recombinant adenovirus containing a truncated N-terminal fragment of the SARS-CoV Spike (S) gene (from--45 to 1469, designated Ad-S(N)), which encoded a truncated S protein (490 amino-acid residues, a part of 672 amino-acid S1 subunit), and investigated whether this construct could induce effective immunity against SARS-CoV in Wistar rats. Rats were immunized either subcutaneously or intranasally with Ad-S(N) once a week for three consecutive weeks. Our results showed that all of the immunized animals generated humoral immunity against the SARS-CoV spike protein, and the sera of immunized rats showed strong capable of protecting from SARS-CoV infection in vitro. Histopathological examination did not find evident side effects in the immunized animals. These results indicate that an adenoviral-based vaccine carrying an N-terminal fragment of the Spike gene is able to elicit strong SARS-CoV-specific humoral immune responses in rats, and may be useful for the development of a protective vaccine against SARS-CoV infection.

Citing Articles

Mitochondrial creatine kinase 1 regulates the cell cycle in non-small cell lung cancer via activation of cyclin-dependent kinase 4.

Yang M, Wang X, Ye Z, Liu T, Meng Y, Duan Y Respir Res. 2023; 24(1):111.

PMID: 37061730 PMC: 10105958. DOI: 10.1186/s12931-023-02417-2.

Oral Delivery of SARS-CoV-2 DNA Vaccines Using Attenuated as a Carrier in Rat.

Zhu D, Mengyue M, Qimuge A, Bilige B, Baiyin T, Temuqile T Mol Gen Microbiol Virol. 2023; 37(3):159-166.

PMID: 36589521 PMC: 9790184. DOI: 10.3103/S0891416822030107.

Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the and families (Review).

Babaeimarzangou S, Zaker H, Soleimannezhadbari E, Gamchi N, Kazeminia M, Tarighi S Exp Ther Med. 2022; 25(1):42.

PMID: 36569444 PMC: 9768462. DOI: 10.3892/etm.2022.11741.

The use of adenoviral vectors in gene therapy and vaccine approaches.

Araujo N, Rubio I, Toneto N, Morale M, Tamura R Genet Mol Biol. 2022; 45(3 Suppl 1):e20220079.

PMID: 36206378 PMC: 9543183. DOI: 10.1590/1678-4685-GMB-2022-0079.

Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.

Elkashif A, Alhashimi M, Sayedahmed E, Sambhara S, Mittal S Clin Transl Immunology. 2021; 10(10):e1345.

PMID: 34667600 PMC: 8510854. DOI: 10.1002/cti2.1345.

References

Bukreyev A, Lamirande E, Buchholz U, Vogel L, Elkins W, St Claire M . Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004; 363(9427):2122-7. PMC: 7112367. DOI: 10.1016/S0140-6736(04)16501-X. View

Cavanagh D . Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 2003; 32(6):567-82. PMC: 7154303. DOI: 10.1080/03079450310001621198. View

Louis N, Evelegh C, Graham F . Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology. 1997; 233(2):423-9. DOI: 10.1006/viro.1997.8597. View

Berger A, Drosten C, Doerr H, Sturmer M, Preiser W . Severe acute respiratory syndrome (SARS)--paradigm of an emerging viral infection. J Clin Virol. 2003; 29(1):13-22. PMC: 7128705. DOI: 10.1016/j.jcv.2003.09.011. View

Xiang Z, Ertl H . Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine. 1999; 17(15-16):2003-8. DOI: 10.1016/s0264-410x(98)00449-6. View

Mizuguchi H, Kay M . Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 1998; 9(17):2577-83. DOI: 10.1089/hum.1998.9.17-2577. View

Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J . Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004; 78(22):12672-6. PMC: 525089. DOI: 10.1128/JVI.78.22.12672-12676.2004. View

Casimiro D, Chen L, Fu T, Evans R, Caulfield M, Davies M . Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003; 77(11):6305-13. PMC: 154996. DOI: 10.1128/jvi.77.11.6305-6313.2003. View

Wu Q, Moraes M, Grubman M . Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine. Virus Res. 2003; 93(2):211-9. DOI: 10.1016/s0168-1702(03)00116-3. View

10.

Graham F, Smiley J, Russell W, Nairn R . Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977; 36(1):59-74. DOI: 10.1099/0022-1317-36-1-59. View

11.

Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey G . Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun. 2004; 319(4):1216-21. PMC: 7111153. DOI: 10.1016/j.bbrc.2004.05.114. View

12.

Delmas B, Rasschaert D, Godet M, Gelfi J, Laude H . Four major antigenic sites of the coronavirus transmissible gastroenteritis virus are located on the amino-terminal half of spike glycoprotein S. J Gen Virol. 1990; 71 ( Pt 6):1313-23. DOI: 10.1099/0022-1317-71-6-1313. View

13.

Yang Z, Huang Y, Ganesh L, Leung K, Kong W, Schwartz O . pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004; 78(11):5642-50. PMC: 415834. DOI: 10.1128/JVI.78.11.5642-5650.2004. View

14.

Guo J, Petric M, Campbell W, McGeer P . SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology. 2004; 324(2):251-6. PMC: 7125913. DOI: 10.1016/j.virol.2004.04.017. View

15.

Correa I, Gebauer F, Bullido M, Sune C, Baay M, Zwaagstra K . Localization of antigenic sites of the E2 glycoprotein of transmissible gastroenteritis coronavirus. J Gen Virol. 1990; 71 ( Pt 2):271-9. DOI: 10.1099/0022-1317-71-2-271. View

16.

Song C, Lee Y, Lee C, Sung H, Kim J, Mo I . Induction of protective immunity in chickens vaccinated with infectious bronchitis virus S1 glycoprotein expressed by a recombinant baculovirus. J Gen Virol. 1998; 79 ( Pt 4):719-23. DOI: 10.1099/0022-1317-79-4-719. View

17.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

18.

Singh H, Raghava G . ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001; 17(12):1236-7. DOI: 10.1093/bioinformatics/17.12.1236. View

19.

Ingallinella P, Bianchi E, Finotto M, Cantoni G, Eckert D, Supekar V . Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A. 2004; 101(23):8709-14. PMC: 423260. DOI: 10.1073/pnas.0402753101. View

20.

Schlagenhauf P, Ashraf H . Severe acute respiratory syndrome spreads worldwide. Lancet. 2003; 361(9362):1017. PMC: 7135903. DOI: 10.1016/s0140-6736(03)12843-7. View